Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013 (2013), Article ID 920595, 11 pages
http://dx.doi.org/10.1155/2013/920595
Review Article

Fluctuating Roles of Matrix Metalloproteinase-9 in Oral Squamous Cell Carcinoma

1Biomedicum Helsinki, Institute of Dentistry, Research Laboratory, University of Helsinki, P.O. Box 63, Haartmaninkatu 8, 00014 Helsinki, Finland
2Department of Diagnostics and Oral Medicine, Institute of Dentistry and the Oulu Center for Cell-Matrix Research, University of Oulu, P.O. Box 5281, 90014 Oulu, Finland
3Oulu University Hospital, Oulu, Finland
4Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Helsinki, Finland

Received 5 November 2012; Accepted 10 December 2012

Academic Editors: S. Bhan, A. Chuang, and J. E. J. Lee

Copyright © 2013 Suvi-Tuuli Vilen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. E. Petersen, “Oral cancer prevention and control—the approach of the World Health Organization,” Oral Oncology, vol. 45, no. 4-5, pp. 454–460, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Nagase, R. Visse, and G. Murphy, “Structure and function of matrix metalloproteinases and TIMPs,” Cardiovascular Research, vol. 69, no. 3, pp. 562–573, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. G. S. Butler and C. M. Overall, “Updated biological roles for matrix metalloproteinases and new “intracellular” substrates revealed by degradomics,” Biochemistry, vol. 48, no. 46, pp. 10830–10845, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Klein and R. Bischoff, “Physiology and pathophysiology of matrix metalloproteases,” Amino Acids, vol. 41, no. 2, pp. 271–290, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Giannelli, J. Falk-Marzillier, O. Schiraldi, W. G. Stetler-Stevenson, and V. Quaranta, “Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5,” Science, vol. 277, no. 5323, pp. 225–228, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. M. D. Sternlicht and Z. Werb, “How matrix metalloproteinases regulate cell behavior,” Annual Review of Cell and Developmental Biology, vol. 17, pp. 463–516, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Egeblad and Z. Werb, “New functions for the matrix metalloproteinases in cancer progression,” Nature Reviews Cancer, vol. 2, no. 3, pp. 161–174, 2002. View at Google Scholar · View at Scopus
  9. E. Hadler-Olsen, B. Fadnes, I. Sylte, L. Uhlin-Hansen, and J. O. Winberg, “Regulation of matrix metalloproteinase activity in health and disease,” FEBS Journal, vol. 278, no. 1, pp. 28–45, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Björklund and E. Koivunen, “Gelatinase-mediated migration and invasion of cancer cells,” Biochimica et Biophysica Acta, vol. 1755, no. 1, pp. 37–69, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Ogata, J. J. Enghild, and H. Nagase, “Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9,” Journal of Biological Chemistry, vol. 267, no. 6, pp. 3581–3584, 1992. View at Google Scholar · View at Scopus
  12. Y. G. Zhao, A. Z. Xiao, R. G. Newcomer et al., “Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells,” Journal of Biological Chemistry, vol. 278, no. 17, pp. 15056–15064, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. S. T. Vilen, P. Nyberg, M. Hukkanen et al., “Intracellular co-localization of trypsin-2 and matrix metalloprotease-9: possible proteolytic cascade of trypsin-2, MMP-9 and enterokinase in carcinoma,” Experimental Cell Research, vol. 314, no. 4, pp. 914–926, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Sorsa, T. Salo, E. Koivunen et al., “Activation of type IV procollagenases by human tumor-associated trypsin- 2,” Journal of Biological Chemistry, vol. 272, no. 34, pp. 21067–21074, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Mazzieri, L. Masiero, L. Zanetta et al., “Control of type IV collagenase activity by the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants,” EMBO Journal, vol. 16, no. 9, pp. 2319–2332, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. P. Han, Y. D. Nien, and W. L. Garner, “Tumor necrosis factor-α-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase,” Journal of Biological Chemistry, vol. 277, no. 30, pp. 27319–27327, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Fridman, M. Toth, D. Pena, and S. Mobashery, “Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2),” Cancer Research, vol. 55, no. 12, pp. 2548–2555, 1995. View at Google Scholar · View at Scopus
  18. D. C. Von Bredow, A. E. Cress, E. W. Howard, G. T. Bowden, and R. B. Nagle, “Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin,” Biochemical Journal, vol. 331, no. 3, pp. 965–972, 1998. View at Google Scholar · View at Scopus
  19. H. Nakamura, Y. Fujii, E. Ohuchi, E. Yamamoto, and Y. Okada, “Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases,” European Journal of Biochemistry, vol. 253, no. 1, pp. 67–75, 1998. View at Google Scholar · View at Scopus
  20. V. Knäuper, B. Smith, C. López-Otin, and G. Murphy, “Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13),” European Journal of Biochemistry, vol. 248, no. 2, pp. 369–373, 1997. View at Google Scholar · View at Scopus
  21. G. J. Peppin and S. J. Weiss, “Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 12, pp. 4322–4326, 1986. View at Google Scholar · View at Scopus
  22. Z. Gu, M. Kaul, B. Yan et al., “S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death,” Science, vol. 297, no. 5584, pp. 1186–1190, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. G. A. Bannikov, T. V. Karelina, I. E. Collier, B. L. Marmer, and G. I. Goldberg, “Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide,” Journal of Biological Chemistry, vol. 277, no. 18, pp. 16022–16027, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. L. E. Graves, E. V. Ariztia, J. R. Navari, H. J. Matzel, M. S. Stack, and D. A. Fishman, “Proinvasive properties of ovarian cancer ascites-derived membrane vesicles,” Cancer Research, vol. 64, no. 19, pp. 7045–7049, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. E. M. Schnaeker, R. Ossig, T. Ludwig et al., “Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion,” Cancer Research, vol. 64, no. 24, pp. 8924–8931, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. S. D. Hong, S. P. Hong, J. I. Lee, and C. Y. Lim, “Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential,” Oral Oncology, vol. 36, no. 2, pp. 207–213, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Brew and H. Nagase, “The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity,” Biochimica et Biophysica Acta, vol. 1803, no. 1, pp. 55–71, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. E. W. Howard, E. C. Bullen, and M. J. Banda, “Preferential inhibition of 72- and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2,” Journal of Biological Chemistry, vol. 266, no. 20, pp. 13070–13075, 1991. View at Google Scholar · View at Scopus
  29. J. P. O'Connell, F. Willenbrock, A. J. P. Docherty, D. Eaton, and G. Murphy, “Analysis of the role of the COOH-terminal domain in the activation, proteolytic activity, and tissue inhibitor of metalloproteinase interactions of gelatinase B,” Journal of Biological Chemistry, vol. 269, no. 21, pp. 14967–14973, 1994. View at Google Scholar · View at Scopus
  30. G. S. Butler, S. S. Apte, F. Willenbrock, and G. Murphy, “Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B: regulation by polyanions,” Journal of Biological Chemistry, vol. 274, no. 16, pp. 10846–10851, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. E. Liu, M. Wang, J. Greene et al., “Preparation and characterization of recombinant tissue inhibitor of metalloproteinase 4 (TIMP-4),” Journal of Biological Chemistry, vol. 272, no. 33, pp. 20479–20483, 1997. View at Publisher · View at Google Scholar · View at Scopus
  32. M. P. S. García, J. M. Suárez-Peñaranda, P. Gayoso-Diz, F. Barros-Angueira, J. M. Gándara-Rey, and A. García-García, “Tissue inhibitor of metalloproteinases in oral squamous cell carcinomas—a therapeutic target?” Cancer Letters, vol. 323, no. 1, pp. 11–19, 2012. View at Publisher · View at Google Scholar
  33. P. D. Brown, “Matrix metalloproteinase inhibitors,” Breast Cancer Research and Treatment, vol. 52, no. 1-3, pp. 125–136, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. C. M. Overall and O. Kleifeld, “Towards third generation matrix metalloproteinase inhibitors for cancer therapy,” British Journal of Cancer, vol. 94, no. 7, pp. 941–946, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. S. M. Wojtowicz-Praga, R. B. Dickson, and M. J. Hawkins, “Matrix metalloproteinase inhibitors,” Investigational New Drugs, vol. 15, no. 1, pp. 61–75, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Zucker, J. Cao, and W. T. Chen, “Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment,” Oncogene, vol. 19, no. 56, pp. 6642–6650, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. L. M. Coussens, B. Fingleton, and L. M. Matrisian, “Matrix metalloproteinase inhibitors and cancer: trials and tribulations,” Science, vol. 295, no. 5564, pp. 2387–2392, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Koivunen, W. Arap, H. Valtanen et al., “Tumor targeting with a selective gelatinase inhibitor,” Nature Biotechnology, vol. 17, no. 8, pp. 768–774, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Heikkilä, J. Suojanen, E. Pirilä et al., “Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides,” International Journal of Cancer, vol. 118, no. 9, pp. 2202–2209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. V. Falk, P. M. Soccal, J. Grünenfelder, G. Hoyt, T. Walther, and R. C. Robbins, “Regulation of matrix metalloproteinases and effect of MMP-inhibition in heart transplant related reperfusion injury,” European Journal of Cardio-Thoracic Surgery, vol. 22, no. 1, pp. 53–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. C. K. Underwood, D. Min, J. G. Lyons, and T. W. Hambley, “The interaction of metal ions and Marimastat with matrix metalloproteinase 9,” Journal of Inorganic Biochemistry, vol. 95, no. 2-3, pp. 165–170, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Björklund, P. Heikkilä, and E. Koivunen, “Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion,” Journal of Biological Chemistry, vol. 279, no. 28, pp. 29589–29597, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. T. A. Sutton, K. J. Kelly, H. E. Mang, Z. Plotkin, R. M. Sandoval, and P. C. Dagher, “Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury,” American Journal of Physiology, vol. 288, no. 1, pp. F91–F97, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. U. Mirastschijski, R. Schnabel, J. Claes, W. Schneider, M. S. Ågren, and J. J. Tomasek, “Matrix metalloproteinase inhibition delays wound healing and blocks the latent transforming growth factor-β1-promoted myofibroblast formation and function,” Wound Repair and Regeneration, vol. 18, no. 2, pp. 223–234, 2010. View at Publisher · View at Google Scholar
  45. H. Hirte, I. B. Vergote, J. R. Jeffrey et al., “A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study,” Gynecologic Oncology, vol. 102, no. 2, pp. 300–308, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. D. R. Shalinsky, J. Brekken, H. Zou et al., “Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials,” Annals of the New York Academy of Sciences, vol. 878, pp. 236–270, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. J. G. Naglich, M. Jure-Kunkel, E. Gupta et al., “Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291,” Cancer Research, vol. 61, no. 23, pp. 8480–8485, 2001. View at Google Scholar · View at Scopus
  48. R. E. B. Seftor, E. A. Seftor, J. E. De Larco et al., “Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis,” Clinical and Experimental Metastasis, vol. 16, no. 3, pp. 217–225, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Sorsa, N. S. Ramamurthy, A. T. Vernillo et al., “Functional sites of chemically modified tetracyclines: inhibition of the oxidative activation of human neutrophil and chicken osteoclast pro-matrix metalloproteinases,” Journal of Rheumatology, vol. 25, no. 5, pp. 975–982, 1998. View at Google Scholar · View at Scopus
  50. L. M. Golub, T. Sorsa, H. M. Lee et al., “Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva,” Journal of Clinical Periodontology, vol. 22, no. 2, pp. 100–109, 1995. View at Google Scholar · View at Scopus
  51. Z. Gu, J. Cui, S. Brown et al., “A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia,” Journal of Neuroscience, vol. 25, no. 27, pp. 6401–6408, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. O. Teronen, M. Laitinen, T. Salo et al., “Inhibition of matrix metalloproteinases by bisphosphonates may in part explain their effects in the treatment of multiple myeloma,” Blood, vol. 96, no. 12, pp. 4006–4007, 2000. View at Google Scholar · View at Scopus
  53. R. Gendron, D. Grenier, T. Sorsa, and D. Mayrand, “Inhibition of the activities of matrix metalloproteinases 2, 8, and 9 by chlorhexidine,” Clinical and Diagnostic Laboratory Immunology, vol. 6, no. 3, pp. 437–439, 1999. View at Google Scholar · View at Scopus
  54. T. N. Mitropoulou, G. N. Tzanakakis, D. Kletsas, H. P. Kalofonos, and N. K. Karamanos, “Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells,” International Journal of Cancer, vol. 104, no. 2, pp. 155–160, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. B. Annabi, M. Bouzeghrane, J. C. Currie et al., “A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis,” Clinical and Experimental Metastasis, vol. 22, no. 5, pp. 429–439, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. O. De Wever and M. Mareel, “Role of tissue stroma in cancer cell invasion,” Journal of Pathology, vol. 200, no. 4, pp. 429–447, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Mareel, M. J. Oliveira, and I. Madani, “Cancer invasion and metastasis: interacting ecosystems,” Virchows Archiv, vol. 454, no. 6, pp. 599–622, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. K. Pietras and A. Östman, “Hallmarks of cancer: interactions with the tumor stroma,” Experimental Cell Research, vol. 316, no. 8, pp. 1324–1331, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. U. Impola, V. J. Uitto, J. Hietanen et al., “Differential expression of matrilysin-I (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer,” Journal of Pathology, vol. 202, no. 1, pp. 14–22, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Sutinen, T. Kainulainen, T. Hurskainen et al., “Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis,” British Journal of Cancer, vol. 77, no. 12, pp. 2239–2245, 1998. View at Google Scholar · View at Scopus
  61. A. Fullár, I. Kovalszky, M. Bitsche et al., “Tumor cell and carcinoma-associated fibroblast interaction regulates matrix metalloproteinases and their inhibitors in oral squamous cell carcinoma,” Experimental Cell Research, vol. 318, no. 13, pp. 1517–1527, 2012. View at Publisher · View at Google Scholar
  62. S. Nurmenniemi, T. Sinikumpu, I. Alahuhta et al., “A novel organotypic model mimics the tumor microenvironment,” American Journal of Pathology, vol. 175, no. 3, pp. 1281–1291, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Suojanen, S.-T. Vilen, P. Nyberg et al., “Selective gelatinase inhibitor peptide is effective in targeting tongue carcinoma cell tumors In Vivo,” Anticancer Research, vol. 31, no. 11, pp. 3659–3664, 2011. View at Google Scholar
  64. K. Wolf, I. Mazo, H. Leung et al., “Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis,” Journal of Cell Biology, vol. 160, no. 2, pp. 267–277, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. A. J. H. Gearing, P. Beckett, M. Christodoulou et al., “Matrix metalloproteinases and processing of pro-TNF-α,” Journal of Leukocyte Biology, vol. 57, no. 5, pp. 774–777, 1995. View at Google Scholar · View at Scopus
  66. A. Ito, A. Mukaiyama, Y. Itoh et al., “Degradation of interleukin 1β by matrix metalloproteinases,” Journal of Biological Chemistry, vol. 271, no. 25, pp. 14657–14660, 1996. View at Publisher · View at Google Scholar · View at Scopus
  67. P. E. Van Den Steen, P. Proost, A. Wuyts, J. Van Damme, and G. Opdenakker, “Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-α and leaves RANTES and MCP-2 intact,” Blood, vol. 96, no. 8, pp. 2673–2681, 2000. View at Google Scholar · View at Scopus
  68. M. Ferreras, U. Felbor, T. Lenhard, B. R. Olsen, and J. M. Delaissé, “Generation and degradation of human endostatin proteins by various proteinases,” FEBS Letters, vol. 486, no. 3, pp. 247–251, 2000. View at Publisher · View at Google Scholar · View at Scopus
  69. R. Heljasvaara, P. Nyberg, J. Luostarinen et al., “Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases,” Experimental Cell Research, vol. 307, no. 2, pp. 292–304, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. S.-I. Kurahara, M. Shinohara, T. Ikebe et al., “Expression of MMPs, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis,” Head and Neck, vol. 21, no. 7, pp. 627–638, 1999. View at Publisher · View at Google Scholar
  71. C. X. Zhou, Y. Gao, N. W. Johnson, and J. Gao, “Immunoexpression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in the metastasis of squamous cell carcinoma of the human tongue,” Australian Dental Journal, vol. 55, no. 4, pp. 385–389, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. C. W. Yorioka, R. D. Coletta, F. Alves, I. N. Nishimoto, L. P. Kowalski, and E. Graner, “Matrix metalloproteinase-2 and -9 activities correlate with the disease-free survival of oral squamous cell carcinoma patients,” International Journal of Oncology, vol. 20, no. 1, pp. 189–194, 2002. View at Google Scholar · View at Scopus
  73. D. Guttman, Y. Stern, T. Shpitzer, D. Ulanovski, T. Druzd, and R. Feinmesser, “Expression of MMP-9, TIMP-1, CD-34 and factor-8 as prognostic markers for squamous cell carcinoma of the tongue,” Oral Oncology, vol. 40, no. 8, pp. 798–803, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Katayama, N. Bandoh, K. Kishibe et al., “Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis,” Clinical Cancer Research, vol. 10, no. 2, pp. 634–640, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. T. Ikebe, M. Shinohara, H. Takcuchi et al., “Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer,” Clinical and Experimental Metastasis, vol. 17, no. 4, pp. 315–323, 1999. View at Publisher · View at Google Scholar · View at Scopus
  76. K. Kato, A. Hara, T. Kuno et al., “Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity,” Journal of Cancer Research and Clinical Oncology, vol. 131, no. 6, pp. 340–346, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. C.-W. Lin, S.-W. Tseng, S.-F. Yang et al., “Role of lipocalin 2 and its complex with matrix metalloproteinase-9 in oral cancer,” Oral Diseases, vol. 18, no. 8, pp. 734–740, 2012. View at Publisher · View at Google Scholar
  78. J. C. De Vicente, M. F. Fresno, L. Villalain, J. A. Vega, and G. Hernández Vallejo, “Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma,” Oral Oncology, vol. 41, no. 3, pp. 283–293, 2005. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Stokes, J. Joutsa, R. Ala-aho et al., “Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma,” Clinical Cancer Research, vol. 16, no. 7, pp. 2022–2035, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. H.-X. Fan, H.-X. Li, Z.-X. Gao, and J.-H. Zheng, “Changes in the expression of MMP2, MMP9, and ColIV in stromal cells in oral squamous tongue cell carcinoma: relationships and prognostic implications,” Journal of Experimental and Clinical Cancer Research, vol. 31, no. 1, article 90, 2012. View at Publisher · View at Google Scholar
  81. M. Siewko, B. Mroczko, and M. Szmitkowski, “The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer,” Folia Histochemica et Cytobiologica, vol. 50, no. 1, pp. 12–19, 2012. View at Publisher · View at Google Scholar
  82. X. Hu, D. Li, W. Zhang, J. Zhou, and B. Tang, “Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion,” Archives of Gynecology and Obstetrics, vol. 26, 2012. View at Publisher · View at Google Scholar
  83. Q. W. Zhang, L. Liu, and R. Chen, “Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 6, pp. 2903–2908, 2012. View at Google Scholar
  84. H. Ruokolainen, P. Pääkkö, and T. Turpeenniemi-Hujanen, “Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker,” International Journal of Cancer, vol. 116, no. 3, pp. 422–427, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. W. G. Stetler-Stevenson, S. Aznavoorian, and L. A. Liotta, “Tumor cell interactions with the extracellular matrix during invasion and metastasis,” Annual Review of Cell Biology, vol. 9, pp. 541–573, 1993. View at Google Scholar · View at Scopus
  86. B. C. Patterson and Q. A. Sang, “Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP.9),” Journal of Biological Chemistry, vol. 272, no. 46, pp. 28823–28825, 1997. View at Publisher · View at Google Scholar · View at Scopus
  87. G. Bergers, R. Brekken, G. McMahon et al., “Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis,” Nature Cell Biology, vol. 2, no. 10, pp. 737–744, 2000. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Mantovani, “Cancer: inflammation by remote control,” Nature, vol. 435, no. 7043, pp. 752–753, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. B. B. Aggarwal, S. Shishodia, S. K. Sandur, M. K. Pandey, and G. Sethi, “Inflammation and cancer: how hot is the link?” Biochemical Pharmacology, vol. 72, no. 11, pp. 1605–1621, 2006. View at Publisher · View at Google Scholar · View at Scopus
  90. D. Ribatti and E. Crivellato, “Mast cells, angiogenesis, and tumour growth,” Biochimica et Biophysica Acta, vol. 1822, no. 1, pp. 2–8, 2012. View at Publisher · View at Google Scholar
  91. L. Sun, M. E. Diamond, A. J. Ottaviano, M. J. Joseph, V. Ananthanarayan, and H. G. Munshi, “Transforming growth factor-β1 promotes matrix metalloproteinase-9- mediated oral cancer invasion through snail expression,” Molecular Cancer Research, vol. 6, no. 1, pp. 10–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Takayama, M. Hatori, Y. Kurihara, Y. Kinugasa, T. Shirota, and S. Shintai, “Inhibition of TGF-β1 suppresses motility and invasiveness of oral squamous cell carcinoma cell lines via modulation of integrins and down-regulation of matrix-metalloproteinases,” Oncology Reports, vol. 21, no. 1, pp. 205–210, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. Q. Yu and I. Stamenkovic, “Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis,” Genes and Development, vol. 14, no. 2, pp. 163–176, 2000. View at Google Scholar · View at Scopus
  94. K. Shchors and G. Evan, “Tumor angiogenesis: cause or consequence of cancer?” Cancer Research, vol. 67, no. 15, pp. 7059–7061, 2007. View at Publisher · View at Google Scholar · View at Scopus
  95. G. Sommer, S. Weise, S. Kralisch et al., “Lipocalin-2 is induced by interleukin-1 β in murine adipocytes in vitro,” Journal of Cellular Biochemistry, vol. 106, no. 1, pp. 103–108, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. H. Watanabe, M. Iwase, M. Ohashi, and M. Nagumo, “Role of interleukin-8 secreted from human oral squamous cell carcinoma cell lines,” Oral Oncology, vol. 38, no. 7, pp. 670–679, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. S. Chakrabarti and K. D. Patel, “Regulation of matrix metalloproteinase-9 release from IL-8-stimulated human neutrophils,” Journal of Leukocyte Biology, vol. 78, no. 1, pp. 279–288, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. S. K. Rao, Z. Pavicevic, Z. Du et al., “Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma,” Journal of Biological Chemistry, vol. 285, no. 42, pp. 32512–32521, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. T. Ishikawa, K. I. Nakashiro, S. Hara et al., “CXCR4 expression is associated with lymph-node metastasis of oral squamous cell carcinoma,” International Journal of Oncology, vol. 28, no. 1, pp. 61–66, 2006. View at Google Scholar · View at Scopus
  100. J. I. Lee, B. H. Jin, M. A. Kim, H. J. Yoon, S. P. Hong, and S. D. Hong, “Prognostic significance of CXCR-4 expression in oral squamous cell carcinoma,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 107, no. 5, pp. 678–684, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. G. Chan, J. O. Boyle, E. K. Yang et al., “Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck,” Cancer Research, vol. 59, no. 5, pp. 991–994, 1999. View at Google Scholar · View at Scopus
  102. Y. E. Kwak, N. K. Jeon, J. Kim, and J. L. Eun, “The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma,” Annals of the New York Academy of Sciences, vol. 1095, pp. 99–112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  103. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at Google Scholar · View at Scopus
  105. J. J. Homer, J. Greenman, and N. D. Stafford, “Angiogenesis in head and neck squamous cell carcinoma,” Clinical Otolaryngology and Allied Sciences, vol. 25, no. 3, pp. 169–180, 2000. View at Publisher · View at Google Scholar · View at Scopus
  106. I. Roodink and W. P. J. Leenders, “Targeted therapies of cancer: angiogenesis inhibition seems not enough,” Cancer Letters, vol. 299, no. 1, pp. 1–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. C. Mǎrgǎritescu, D. Pirici, C. Simionescu et al., “VEGF and VEGFRs expression in oral squamous cell carcinoma,” Romanian Journal of Morphology and Embryology, vol. 50, no. 4, pp. 527–548, 2009. View at Google Scholar · View at Scopus
  108. D. Shweiki, M. Neeman, A. Itin, and E. Keshet, “Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 3, pp. 768–772, 1995. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Stewart, H. Siavash, C. Hebert, K. Norris, N. G. Nikitakis, and J. J. Sauk, “Phenotypic switching of VEGF and collagen XVIII during hypoxia in head and neck squamous carcinoma cells,” Oral Oncology, vol. 39, no. 8, pp. 862–869, 2003. View at Publisher · View at Google Scholar · View at Scopus
  110. A. K. Olsson, A. Dimberg, J. Kreuger, and L. Claesson-Welsh, “VEGF receptor signalling—in control of vascular function,” Nature Reviews Molecular Cell Biology, vol. 7, no. 5, pp. 359–371, 2006. View at Publisher · View at Google Scholar · View at Scopus
  111. J. A. Forsythe, B. H. Jiang, N. V. Iyer et al., “Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1,” Molecular and Cellular Biology, vol. 16, no. 9, pp. 4604–4613, 1996. View at Google Scholar · View at Scopus
  112. C. J. Liu, K. W. Chang, S. C. Lin, and H. W. Cheng, “Presurgical serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinoma,” Oral Oncology, vol. 45, no. 10, pp. 920–925, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. S. P. Osinsky, I. I. Ganusevich, L. N. Bubnovskaya et al., “Hypoxia level and matrix metalloproteinases-2 and -9 activity in lewis lung carcinoma: correlation with metastasis,” Experimental Oncology, vol. 27, no. 3, pp. 202–205, 2005. View at Google Scholar · View at Scopus
  114. S. Hiratsuka, K. Nakamura, S. Iwai et al., “MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis,” Cancer Cell, vol. 2, no. 4, pp. 289–300, 2002. View at Publisher · View at Google Scholar · View at Scopus
  115. A. C. Henriques, F. R. de Matos, H. C. Galvão, and R. A. Freitas, “Immunohistochemical expression of MMP-9 and VEGF in squamous cell carcinoma of the tongue,” Journal of Oral Science, vol. 54, no. 1, pp. 105–111, 2012. View at Publisher · View at Google Scholar
  116. S. H. Kim, K. Kim, J. S. Lee, B. S. Koo, J. H. Kim, and E. C. Choi, “Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression,” Journal of Surgical Oncology, vol. 93, no. 4, pp. 330–337, 2006. View at Publisher · View at Google Scholar
  117. N. G. Nikitakis, H. Rivera, M. A. Lopes et al., “Immunohistochemical expression of angiogenesis-related markers in oral squamous cell carcinomas with multiple metastatic lymph nodes,” American Journal of Clinical Pathology, vol. 119, no. 4, pp. 574–586, 2003. View at Publisher · View at Google Scholar · View at Scopus
  118. A. Väänänen, M. Ylipalosaari, M. Parikka et al., “Collagen XVIII modulation is altered during progression of oral dysplasia and carcinoma,” Journal of Oral Pathology and Medicine, vol. 36, no. 1, pp. 35–42, 2007. View at Publisher · View at Google Scholar · View at Scopus
  119. J. J. Homer, J. Greenman, and N. D. Stafford, “Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma,” Clinical Otolaryngology and Allied Sciences, vol. 27, no. 1, pp. 32–37, 2002. View at Publisher · View at Google Scholar · View at Scopus
  120. P. Nyberg, P. Heikkilä, T. Sorsa et al., “Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13,” Journal of Biological Chemistry, vol. 278, no. 25, pp. 22404–22411, 2003. View at Publisher · View at Google Scholar · View at Scopus
  121. F. Peng, Z. Xu, J. Wang et al., “Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models,” PLoS ONE, vol. 7, no. 4, Article ID e34646, 2012. View at Publisher · View at Google Scholar
  122. M. S. O'Reilly, L. Holmgren, Y. Shing et al., “Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma,” Cell, vol. 79, no. 2, pp. 315–328, 1994. View at Publisher · View at Google Scholar · View at Scopus
  123. A. Pozzi, W. F. LeVine, and H. A. Gardner, “Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis,” Oncogene, vol. 21, no. 2, pp. 272–281, 2002. View at Publisher · View at Google Scholar · View at Scopus
  124. G. Matsumoto, Y. Ohmi, and J. Shindo, “Angiostatin gene therapy inhibits the growth of murine squamous cell carcinoma in vivo,” Oral Oncology, vol. 37, no. 4, pp. 369–378, 2001. View at Publisher · View at Google Scholar · View at Scopus
  125. Y. Hamano, M. Zeisberg, H. Sugimoto et al., “Physiological levels of tumstatin, a fragment of collagen IV α3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via αVβ3 integrin,” Cancer Cell, vol. 3, no. 6, pp. 589–601, 2003. View at Publisher · View at Google Scholar · View at Scopus
  126. Y. Maeshima, M. Manfredi, C. Reimerli et al., “Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin,” Journal of Biological Chemistry, vol. 276, no. 18, pp. 15240–15248, 2001. View at Publisher · View at Google Scholar · View at Scopus
  127. S. Choi and J. N. Myers, “Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy,” Journal of Dental Research, vol. 87, no. 1, pp. 14–32, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. D. M. Walker, G. Boey, and L. A. McDonald, “The pathology of oral cancer,” Pathology, vol. 35, no. 5, pp. 376–383, 2003. View at Publisher · View at Google Scholar · View at Scopus
  129. M. G. C. T. Van Oijen and P. J. Slootweg, “Oral field cancerization: carcinogen-induced independent events or micrometastatic deposits?” Cancer Epidemiology Biomarkers and Prevention, vol. 9, no. 3, pp. 249–256, 2000. View at Google Scholar · View at Scopus
  130. E. Vairaktaris, S. Vassiliou, E. Nkenke et al., “A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma,” European Journal of Surgical Oncology, vol. 34, no. 4, pp. 450–455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  131. R. Tamamura, H. Nagatsuka, C. H. Siar et al., “Comparative analysis of basal lamina type IV collagen alpha chains, matrix metalloproteinases-2 and -9 expressions in oral dysplasia and invasive carcinoma,” Acta Histochemica. In press.
  132. R. C. K. Jordan, M. Macabeo-Ong, C. H. Shiboski et al., “Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer,” Clinical Cancer Research, vol. 10, no. 19, pp. 6460–6465, 2004. View at Publisher · View at Google Scholar · View at Scopus
  133. K. U. Ogbureke, P. M. Weinberger, S. W. Looney et al., “Expressions of matrix metalloproteinase-9 (MMP-9), dentin sialophosphoprotein (DSPP), and osteopontin (OPN) at histologically negative surgical margins may predict recurrence of oral squamous cell carcinoma,” Oncotarget, vol. 3, no. 3, pp. 286–298, 2012. View at Google Scholar
  134. L. M. Coussens, C. L. Tinkle, D. Hanahan, and Z. Werb, “MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis,” Cell, vol. 103, no. 3, pp. 481–490, 2000. View at Google Scholar · View at Scopus
  135. T. Ramqvist and T. Dalianis, “Oropharyngeal cancer epidemic and human papillomavirus,” Emerging Infectious Diseases, vol. 16, no. 11, pp. 1671–1677, 2010. View at Publisher · View at Google Scholar · View at Scopus
  136. M. A. Andreoli, C. di Loreto, A. L. Filho, L. L. Villa, and S. S. Maria-Engler, “HPV16 oncoproteins induce MMPs/RECK-TIMP-2 imbalance in primary keratinocytes: possible implications in cervical carcinogenesis,” PLoS ONE, vol. 7, no. 3, Article ID e33585, 2012. View at Publisher · View at Google Scholar
  137. S.-T. Vilen, J. Suojanen, F. Salas et al., “Trypsin-2 enhances carcinoma invasion by processing tight junctions and activating promt1-mmp,” Cancer Investigation, vol. 30, no. 8, pp. 583–592, 2012. View at Publisher · View at Google Scholar
  138. E. Pirilä, P. Maisi, T. Salo, E. Koivunen, and T. Sorsa, “In vivo localization of gelatinases (MMP-2 and -9) by in situ zymography with a selective gelatinase inhibitor,” Biochemical and Biophysical Research Communications, vol. 287, no. 3, pp. 766–774, 2001. View at Publisher · View at Google Scholar · View at Scopus
  139. P. A. M. Snoek-van Beurden and J. W. Von Den Hoff, “Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors,” BioTechniques, vol. 38, no. 1, pp. 73–83, 2005. View at Google Scholar · View at Scopus
  140. L. Jin and R. V. Lloyd, “In situ hybridization: methods and applications,” Journal of Clinical Laboratory Analysis, vol. 11, no. 1, pp. 2–9, 1997. View at Google Scholar
  141. R. D. Singh, N. Haridas, J. B. Patel et al., “Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer,” Indian Journal of Clinical Biochemistry, vol. 25, no. 3, pp. 250–259, 2010. View at Publisher · View at Google Scholar · View at Scopus
  142. B. P. Patel, S. V. Shah, S. N. Shukla, P. M. Shah, and P. S. Patel, “Clinical significance of MMP-2 and MMP-9 in patients with oral cancer,” Head and Neck, vol. 29, no. 6, pp. 564–572, 2007. View at Publisher · View at Google Scholar · View at Scopus
  143. J. M. Berg, J. L. Tymoczko, and L. Stryer, Biochemistry, W.H. Freeman, New York, NY, USA, 5th edition, 2002.
  144. J. Suojanen, T. Salo, E. Koivunen, T. Sorsa, and E. Pirilä, “A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMp) inhibitor reduces cancer cell motility and tumor growth,” Cancer Biology and Therapy, vol. 8, no. 24, pp. 2362–2370, 2009. View at Google Scholar · View at Scopus
  145. K. Hotary, X. Y. Li, E. Allen, S. L. Stevens, and S. J. Weiss, “A cancer cell metalloprotease triad regulates the basement membrane transmigration program,” Genes and Development, vol. 20, no. 19, pp. 2673–2686, 2006. View at Publisher · View at Google Scholar · View at Scopus
  146. H. Luukkaa, P. Klemi, I. Leivo et al., “Expression of matrix metalloproteinase-1, -7, -9, -13, Ki-67, and HER-2 in epithelial-myoepithelial salivary gland cancer,” Head and Neck, vol. 32, no. 8, pp. 1019–1027, 2010. View at Publisher · View at Google Scholar · View at Scopus
  147. C. Bendrik, J. Robertson, J. Gauldie, and C. Dabrosin, “Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo,” Cancer Research, vol. 68, no. 9, pp. 3405–3412, 2008. View at Publisher · View at Google Scholar · View at Scopus
  148. P. Garg, D. Sarma, S. Jeppsson et al., “Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer,” Cancer Research, vol. 70, no. 2, pp. 792–801, 2010. View at Publisher · View at Google Scholar · View at Scopus